This Week in Cardiology

Dec 19 2025 This Week in Cardiology

The MI paradox of risk scores, the CELEBRATE trial of a new subcutaneous glycoprotein IIb/IIIA inhibitor (with its funny endpoint), the SURPASS CVOT trial, and the bad story of andexanet alfa are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I What do risk scores mean for individuals? Or perhaps a better question: Is a first MI preventable? * Limitations of Screening in Predicting First MI https://www.jacc.org/doi/10.1016/j.jacadv.2025.102361 * Sudden Death Due to Cardiac Arrhythmias https://www.nejm.org/doi/abs/10.1056/NEJMra000650 * UMC Amsterdam group (EHJ) https://academic.oup.com/eurheartj/article/46/38/3762/8181058 II CELEBRATE Trial * CELEBRATE Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268 III SURPASS CVOT Trial Published Aug 01, 2025 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1002781 * SURPASS-CVOT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2505928 * REWIND Trial 10.1016/S0140-6736(19)31149-3 External Link IV FDA Pulls Andexanet Alfa From the Market * ANNEXA 4 https://www.nejm.org/doi/10.1056/NEJMoa1814051 * ANNEXA I https://www.nejm.org/doi/full/10.1056/NEJMoa2313040 * Richard Buka Tweet https://x.com/richardbuka/status/2001045834050216327?s=20 V Mandrola's Top Cardiovascular Stories of 2025 https://www.medscape.com/viewarticle/mandrolas-top-10-cardiovascular-stories-2025-2025a1000yuh You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Dec 12 2025 This Week in Cardiology

An elegant study in post-TAVI atrioventricular block, a PSA for my structural colleagues, revascularization in women, and a CTO PCI trial are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I AV Block After TAVR Heart Blocks During vs After TAVR Show Distinct Patterns https://www.medscape.com/viewarticle/heart-blocks-during-vs-after-tavr-show-distinct-patterns-2025a1000ypp * Mechanisms Underlying Alterations in Cardiac Conduction After TAVR https://jamanetwork.com/journals/jamacardiology/fullarticle/2842748 II Related PSA Announcement to My Structural Colleagues III Revascularization Strategies in Women with Severe Chronic CAD Women With Chronic Severe CAD Fare Better With CABG vs PCI https://www.medscape.com/viewarticle/women-chronic-severe-cad-fare-better-cabg-vs-pci-2025a1000ygd * PCI vs CABG in Women With Chronic CAD https://doi.org/10.1093/eurheartj/ehaf806 * PCI vs CABG - Meta-Analysis of 4 RCTs https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02334-5/abstract * CABG vs Drug-Eluting Stent Implantation for CAD - Meta-Analysis https://www.jacc.org/doi/10.1016/j.jcin.2016.10.008 * RECHARGE trial https://therechargetrial.com/ IV A CTO PCI RCT – But don't get your hopes up * Early vs Late-Staged PCI After Subintimal Tracking and Re-entry for CTO https://doi.org/10.1016/j.jacc.2025.09.1598 * DECISION CTO trial https://pubmed.ncbi.nlm.nih.gov/30813758/ * National Inpatient Sample Database PCI CTO Associated With Higher Mortality https://pubmed.ncbi.nlm.nih.gov/37356643/ V Mandrola's Top 10 Stories You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Dec 05 2025 This Week in Cardiology

Less is more after PCI, the TARGET-FIRST trial, a negative blood pressure trial that is actually positive, aspirin vs OAC for bleeding, AEDs, and Factor XI is not dead yet are the topics discussed by John Mandrola, MD, on this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Less is More: TARGET-FIRST * TARGET-FIRST Trial https://www.nejm.org/doi/10.1056/NEJMoa2508808 * STOPDAPT-2 ACS Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2789701 II A Negative Trial That Is Actually Positive * The RETREAT-FRAIL Study https://www.nejm.org/doi/full/10.1056/NEJMoa2508157 III Major Bleeding With Aspirin vs Apixaban * Subanalysis of ARTESiA https://jamanetwork.com/journals/jamacardiology/fullarticle/2841075 * ARTESiA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2310234 * AVERROES Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1007432 IV High Value Interventions – The AED * Experts Call for AED Placement on All Commercial Aircraft https://www.medscape.com/viewarticle/experts-call-aed-placement-all-commercial-aircraft-2025a1000xzf * In-Flight Sudden Cardiac Arrest and AED Use 10.1016/j.cjca.2025.10.010 External Link V Factor XI Inhibitors – OCEANIC STROKE trial * Bayer Press Release on Asundexian https://www.bayer.com/en/us/news-stories/oceanic-stroke You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Nov 21 2025 This Week in Cardiology

Listener feedback, huge news in the world of carotid disease with the CREST-2 publication, prasugrel beats ticagrelor again, and a big coffee trial are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback * Complete Revascularization for Acute MI Meta-analysis https://doi.org/10.1016/S0140-6736(25)02170-1 II A Sea Change in the Treatment of Carotid Artery Disease — CREST-2 Published * ECST-2 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00107-3/fulltext * SPACE-2 https://pubmed.ncbi.nlm.nih.gov/36115360/ * CREST-2 Trial www.nejm.org/doi/full/10.1056/NEJMoa2508800 * CREST Protocol paper https://pmc.ncbi.nlm.nih.gov/articles/PMC5987521/ III Prasugrel Beats Ticagrelor in High-Risk Patients With Diabetes After PCI https://www.medscape.com/viewarticle/prasugrel-beats-ticagrelor-high-risk-patients-diabetes-after-2025a1000wbt * PLATO trial https://www.nejm.org/doi/full/10.1056/NEJMoa0904327 * Ticagrelor or prasugrel vs clopidogrel in PCI https://eurointervention.pcronline.com/article/ticagrelor-or-prasugrel-versus-clopidogrel-in-patients-undergoing-percutaneous-coronary-intervention-for-chronic-coronary-syndromes * ISAR-REACT 5 trial https://www.nejm.org/doi/full/10.1056/NEJMoa1908973 IV Another Coffee and AF study Can Coffee Cut the Risk for Atrial Fibrillation? https://www.medscape.com/viewarticle/can-coffee-cut-risk-atrial-fibrillation-2025a1000w11 A Coffee a Day to Keep the AFib Away? The DECAF Trial Discussed https://www.medscape.com/viewarticle/coffee-day-keep-afib-away-decaf-trial-discussed-2025a1000v5z * DECAF trial https://jamanetwork.com/journals/jama/fullarticle/2841253 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Nov 14 2025 This Week in Cardiology

Listener feedback on the PISCES trial, AHA news (including a big PCSK9i trial), beta-blockers post MI, LAAC, and post-AF ablation OAC use are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Why I Believe Fish Oil's Big CV Benefit in Dialysis Patients https://www.medscape.com/viewarticle/why-i-believe-fish-oils-big-cv-benefit-dialysis-patients-2025a1000uzg * PISCES trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513032 II PCSK9 Inhibitor News In Global Trial, PCSK9 Inhibitor Provides Major Protection Against First CV Event https://www.medscape.com/viewarticle/global-trial-pcsk9-inhibitor-provides-major-protection-2025a1000uzp * VESALIUS-CV trial https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 * ODYSSEY trial https://www.nejm.org/doi/full/10.1056/NEJMoa1801174 * FOURIER https://www.nejm.org/doi/full/10.1056/NEJMoa1615664 * Anish Koka Tweet on LDL-lowering https://x.com/anish_koka/status/1987280506937909326?s=20 III Beta-Blockers After MI and John Cleland * Beta-Blockers after MI with normal EF https://www.nejm.org/doi/full/10.1056/NEJMoa2512686 * REBOOT-CNIC trial https://www.nejm.org/doi/full/10.1056/NEJMoa2504735 * REDUCE AMI trial https://academic.oup.com/ehjcvp/article/9/2/192/6895544?login=false * ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204 * CAPITAL RCT trial https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199347 * Beta-Blockers after MI with mildly reduced EF https://pubmed.ncbi.nlm.nih.gov/40897190/ * John Cleland Clinical Outlook https://www.nature.com/articles/s41569-025-01228-w IV Left Atrial Appendage Closure – The CLOSURE-AF trial Percutaneous LAAC in AF Falls Short Again in CLOSURE-AF https://www.medscape.com/viewarticle/percutaneous-left-atrial-appendage-closure-af-falls-short-2025a1000uzu * Prague-17 Trial https://www.jacc.org/doi/10.1016/j.jacc.2020.04.067 * OPTION trial https://www.nejm.org/doi/full/10.1056/NEJMoa2408308 V Oral AC after AF ablation – the OCEAN Trial Anticoagulation After AF Ablation: The OCEAN Trial Still Leaves Questions https://www.medscape.com/viewarticle/anticoagulation-after-af-ablation-ocean-trial-still-leaves-2025a1000v4t * OCEAN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509688 * ALONE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2838294 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net